Roy Wallace, MD
Retina Specialist · Nashville, TNNPI 1417946203
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (49.9%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 88.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $12,291 and has fallen 96.2% since, to $465 in 2025.
Across 104 payments — averaging $183.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$17K
- Regeneron Healthcare Solutions, Inc.$805
- Alimera Sciences, Inc.$342
- Genentech USA, Inc.$290
- AbbVie$188
- Astellas Pharma US Inc$152
- plus $512 from 10 others
What the payments were for
- Food & beverage$2,26912%
- Education$200%
- Ownership interest$7,26238%
- Other$9,50250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $16,764 |
| Regeneron Healthcare Solutions, Inc. | 29 | $805 |
| Alimera Sciences, Inc. | 17 | $342 |
| Genentech USA, Inc. | 13 | $290 |
| AbbVie(2 entities) | 10 | $188 |
| Astellas Pharma US Inc | 6 | $152 |
| Apellis Pharmaceuticals, Inc. | 5 | $107 |
| ANI Pharmaceuticals, Inc. | 3 | $97 |
| Biogen | 4 | $85 |
| Coherus Oncology, Inc. | 2 | $53 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $47 |
| Novartis | 2 | $35 |
| Sandoz | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Neurotech Pharmaceuticals, Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$119
How this compares
$19,053 in reported general payments places this provider in the 75th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 85 | $3,858 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 209 | $3,609 |
| Brimonidine Tartrate | 54 | $3,362 |
| Latanoprost | 146 | $1,809 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,565 |
| Timolol Maleate | 118 | $1,193 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 94 | $1,141 |
| Dorzolamide Hcl | 27 | $849 |
| Ketorolac Tromethamine | 42 | $513 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Nashville
- Carl AwhNashville$1.3M
- Peter SonkinNashville$949K
- Brandon BusbeeNashville$566K
- Eric SchneiderNashville$134K
- David ReichsteinNashville$114K
- Akshay ThomasNashville$108K
- Franco RecchiaNashville$72K
- Everton ArrindellNashville$39K
- Kenneth MoffatNashville$17K
- Brigid MarshallNashville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.